GlassScriptPhysician profile
Keri A Loftus
NPI 1649569518
$4,007.49
in general payments reported to CMS, 2019-2025
38 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $305 · 2023: $1,120 · 2024: $1,104 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360 · Education: $27.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,359.80 |
| Education | $27.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,511.67 | 2023-2025 | Fasenra, Breztri, Airsupra |
| Grifols USA, LLC | $270.68 | 2023-2025 | Prolastin-C Liquid |
| Insmed, INC. | $172.98 | 2024-2025 | Arikayce |
| Medtronic, INC. | $170.02 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $156.49 | 2023-2025 | Dupixent |
| Abbvie INC. | $149.73 | 2021-2022 | |
| Harmony Biosciences LLC | $147.97 | 2023-2024 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.24 | 2023-2025 | Ofev, Spiriva Respimat, Jascayd |
| United Therapeutics Corporation | $105.83 | 2023-2024 | |
| Electromed, INC. | $100.23 | 2023-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $86.88 | 2025 | Winrevair |
| Takeda Pharmaceuticals U.S.A., INC. | $74.95 | 2021-2025 | Glassia |
| Jazz Pharmaceuticals INC. | $70.53 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $68.94 | 2024-2025 | Lumryz |
| Amgen INC. | $68.62 | 2023-2025 | Tezspire |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Loftus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.